Drug Safety

, Volume 10, Issue 5, pp 406–412 | Cite as

Topical Corticosteroids and Unwanted Local Effects

Improving the Benefit/Risk Ratio
  • Moira Mori
  • Nicola Pimpinelli
  • Benvenuto Giannotti
Review Article Risk-Benefit Assessment


The main goal of pharmacological research in the field of topical corticosteroids (TCs) is to dissociate efficacy and adverse effects as much as possible. The optimal use of TCs, i.e. the careful evaluation of the benefit/risk ratio, depends on: (i) the chemical structure of the TC; (ii) the type of vehicle; (iii) the mode of application; and (iv) the features of the skin to be treated. The recent availability of TCs characterised by a good dissociation between efficacy and adverse effects makes the classic and widely used classification system of TCs based upon potency out of date. Indeed, TCs with increasing potency have been characterised up to now, as a rule, by an increasing risk of adverse effects. Therefore, a classification system taking into major account the benefit/risk ratio seems particularly needed for clinical use in dermatology.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Barry BW. Bioavailability of topical steroids. Dermatologica 152 (Suppl. 1): 47–65, 1976PubMedCrossRefGoogle Scholar
  2. Bateman DN. Clinical pharmacology of topical steroids. In Greaves MW & Shuster S (Eds) Pharmacology of the skin II, pp. 239–249, Springer, Berlin, 1989CrossRefGoogle Scholar
  3. Bodor N, Farag HH. Improved delivery through biological membranes. Journal of Medicinal Chemistry 26: 313–318, 1983PubMedCrossRefGoogle Scholar
  4. Budgaard H, Hansen J. Studies on the stability of cortico steroids. Kinetics of the rearrangement of betamethasone-17-valerate to the 21-valerato ester in aqueous solution. International Journal of Pharmaceutics 7: 197–203, 1981CrossRefGoogle Scholar
  5. Chernosky ME, Schmidt JD. Atrophy, telangiectasia and purpura after topical fluorinated corticosteroid therapy. Cutis 13: 383–386, 1974Google Scholar
  6. Cheung YW, Liwan PA, Irwin WJ. Resistance to enzymatic hydrolysis as a pameter in drug potency. International Journal of Pharmaceutics 27: 325–333, 1985CrossRefGoogle Scholar
  7. Cullen Si. Effective topical dermatologic therapy. Dermatologic Clinics 7: 37–42, 1989PubMedGoogle Scholar
  8. Deakin MJ. Current dangers and problems in the topical use of steroids. Medical Journal of Australia 1: 120–121, 1976PubMedGoogle Scholar
  9. du Vivier A. Tachyphylaxis to topically applied steroids. Archives of Dermatology 112: 1245–1248, 1976PubMedCrossRefGoogle Scholar
  10. Dykes PJ, Hill S, Marks R. Assessment of the atrophogenicity potential of glucocorticoids by ultrasound and by epidermal biopsy under occlusive and nonocclusive conditions. In Christophers E, Kligman AM, Schoepf E, et al. (Eds) Topical corticosteroid therapy, pp. 111–118, Raven Press, New York, 1988Google Scholar
  11. Elias PM, Cooper ER, Korc A, et al. Percutaneous transport in relation to stratum corneum structure and lipid composition. Journal of Investigative Dermatology 76: 297–301, 1981PubMedCrossRefGoogle Scholar
  12. Frosch PJ, Behrenbeck EM, Frosch K, et al. The Duhring chamber assay for corticosteroid atrophy. British Journal of Dermatology 104: 57–65, 1981PubMedCrossRefGoogle Scholar
  13. Fusaro RM. Flexibile classification for the clinical potency of topical corticosteroid proprietaries. Drug Intelligence and Clinical Pharmacy 22: 412–415, 1988PubMedGoogle Scholar
  14. Giannotti B. Current treatment guidelines for topical corticosteroids. Drugs 36 (Suppl. 5): 9–14, 1988PubMedCrossRefGoogle Scholar
  15. Giannotti B, Pimpinelli N. Topical corticosteroids. Which drug and when? Drugs 44: 65–71, 1992Google Scholar
  16. Goermar FE, Bernd A, Holzmann H, et al. Wirkung von hydro cortisonaceponat auf proliferation, gesamtprotein-und kollagensynthese menschlicher hautfibroblasten in vitro. Arzneimittelforschung (Drug Res) 28: 342–344, 1990Google Scholar
  17. Haneke E. The treatment of atopic dermatitis with methylprednisolone aceponate (MPA), a new topical corticosteroid. Journal of Dermatological Treatment 3 (Suppl. 2): 13–15, 1992CrossRefGoogle Scholar
  18. Haynes Jr RC. Adrenocorticotrophic hormone: adrenocortical steroids and their synthetic analogs; inhibitors of the synthesis and actions of adrenocortical hormones. In Gilman et al. (Eds) The pharmacological basis of therapeutics, 8th ed., pp. 1431–1462 and 1573–1576, Pergamon Press, New York, 1990Google Scholar
  19. Katz HI, Prawer SE, Watson MJ, et al. Mometasone furoate ointment 0.1% vs. hydrocortisone ointment 1.0% in psoriasis. International Journal of Dermatology 28: 342–344, 1989PubMedCrossRefGoogle Scholar
  20. Katz M, Shaikh ZI. Percutaneous corticosteroid absorption correlated to partition coefficient. Journal of Pharmaceutical Sciences 54: 591–594, 1965PubMedCrossRefGoogle Scholar
  21. Kecskes A, Heger-Mahn D, Kuhlmann K, et al. Comparison of the local and systemic side effects of methylprednisolone aceponate and mometasone furoate applied as ointment with equal anti-inflammatory activity. Journal of the American Academy of Dermatology 29: 576–580, 1993PubMedCrossRefGoogle Scholar
  22. Kerscher MJ, Korting HC.Topical glucocorticoids of the non-fluorinated double-ester type. Lack of atrophogeneicity in normal skin as assessed by high-frequency ultrasound. Acta Dermato-Venereologica (Stockholm) 72: 214–216, 1992Google Scholar
  23. Kligman AM, Frosch PJ. Steroid addiction. International Journal of Dermatology 112: 1115–1117, 1979Google Scholar
  24. Kligman AM. Adverse effects of topical corticosteroids. In Christophers E, Schopf E, Kligman AM, et al. (Eds) Topical corticosteroid therapy: a novel approach to safer drugs, pp. 181–187, Raven Press, New York, 1988Google Scholar
  25. Koch EMM, Ott R. Comparative study on the potency of topical corticoid preparations using various methods of testing. Hautarzt 63: 177–183, 1988Google Scholar
  26. Korting HC, Kerscher MJ, Schaefer-Korting M. Topical glucocorticoids with improved benefit/risk ratio: do they exist? Journal of the American Academy of Dermatology 27: 87–92,1992PubMedCrossRefGoogle Scholar
  27. Korting HG, Vieluf D, Kerscher M. 0.25% prednicarbate cream and the corresponding vehicle induce less skin atrophy than 0.1% betamethasone 17-valerate cream and 0.05% clobetasol propionate cream. European Journal of Clinical Pharmacology, in press, 1994Google Scholar
  28. Korting HC, Zienicke H, Schafer-Korting M, et al. Liposome encapsulation improves efficacy of betamethasone dipropionate in atopic eczema but not in psoriasis vulgaris. European Journal of Clinical Pharmacology 39: 349–351, 1990PubMedCrossRefGoogle Scholar
  29. Lavker RM, Schechter NM, Lazarus GS. Effects of topical corticosteroids on human dermis. British Journal of Dermatology 115: 101–107, 1986PubMedCrossRefGoogle Scholar
  30. Lehman P, Zheng P, Lavker RM, et al. Corticosteroid atrophy in human skin. A study by light, scanning and transmission electron microscopy. Journal of Investigative Dermatology 81: 169–176, 1983CrossRefGoogle Scholar
  31. Lesnik RH, Mezick JA, Capetola R, et al. Topical all-trans retinoic acid prevents corticosteroid-induced skin atrophy without abrogating the anti-inflammatory effect. Journal of the American Academy of Dermatology 21: 186–190, 1989PubMedCrossRefGoogle Scholar
  32. Maibach HI, Stoughton RB. Topical corticosteroids. In Azarnoff DL (Ed.) Steroid therapy, pp. 174–90, Saunders, Philadelphia, 1975Google Scholar
  33. McKenzie AW, Stoughton RB. Method comparing percutaneous absorption of steroids. Archives of Dermatology 88: 608–610, 1962CrossRefGoogle Scholar
  34. Meyer E, Smith EW, Haigh JM, et al. Potency ranking of two new topical corticosteroid creams containing 0,1% desonide or 0,05 halometasone utilising human skin blanching assay. Arzneimittelforschung (Drug Res) 38: 1840–1843, 1988Google Scholar
  35. Miller JA, Monroe DD. Topical corticosteroids: clinical pharmacology and therapeutic use. Drugs 19: 119–134, 1990CrossRefGoogle Scholar
  36. Nilsson JE, Gip LJ. Systemic effects of local treatment with high doses of potent corticosteroids in psoriasis. Acta DermatoVenereologica (Stockholm) 59: 245–248, 1979Google Scholar
  37. Ortonne JR Clinical potential of topical corticosteroids. Drugs 36: 38–42, 1988PubMedCrossRefGoogle Scholar
  38. Ortonne JR Safety aspects of topical methylprednisolone aceponate (MPA) treatment. Journal of Dermatological Treatment 3 (Suppl. 2): 21–25, 1992CrossRefGoogle Scholar
  39. Parish LC, Witkowsky JA, Millikan LE, et al. The potency, efficacy, and usage of superpotent topical corticosteroids. International Journal of Dermatology 29: 709–710, 1990PubMedCrossRefGoogle Scholar
  40. Phillips GH. Locally active corticosteroids: structure-activity relationship. In Wilson L & Marks R (Eds) Mechanism of topical corticosteroid activity, pp. 1–6, Churchill Livingstone, Edinburgh, 1976Google Scholar
  41. Robertson DB, Maibach HI. Topical corticosteroids. International Journal of Dermatology 21: 59–67, 1982PubMedCrossRefGoogle Scholar
  42. Rousseau GG, Schmidt JP. Structure-activity relationships for glucocorticoids. Determination of receptor binding and biological activity. Journal of Steroid Biochemistry and Molecular Biology 8: 911–919, 1977Google Scholar
  43. Sarnaky I, Hadgraft J, Caron GA, et al. The role of vehicle in the percutaneous absorption of corticosteroids. An experimental and clinical study. British Journal of Dermatology 77: 569–575, 1965CrossRefGoogle Scholar
  44. Shapiro EL, Gentles MJ, Tiberi RL, et al. 17-Heteroaroyl esters of corticosteroids, 2, 11-beta-hydroxy series. Journal of Medicinal Chemistry 30: 1581–1588, 1987PubMedCrossRefGoogle Scholar
  45. Stefanovic DV, Wilson L, Sparkes CG. A separation of clinical from epidermal thinning effect in the topical glucocorticoid clobetasone butyrate. British Journal of Dermatology 96: 67–70, 1977CrossRefGoogle Scholar
  46. Stoughton RB, Cornell RC. Review of super-potent corticosteroids. Seminars in Dermatology 6: 72–76, 1987Google Scholar
  47. Takeda K, Arase S, Takahashi S. Side effects of topical corticosteroids and their prevention. Drugs 36 (Suppl. 5): 15–23, 1988PubMedCrossRefGoogle Scholar
  48. Tauber U. Drug metabolism in the skin: advantages and disadvantages. In Hadgraft J & Guy RH (Eds) Transdermal drug delivery: development issues and research initiatives, pp. 99–107, Dekker-Verlag, New York, Basel, 1989Google Scholar
  49. Thalen A, Brattsand R, Andersson PH. Development of glucocorticoids with enhanced ratio between topical and systemic effects. Acta Dermato-Venereologica (Stockholm) 69 (Suppl. 151): 11–19, 1989Google Scholar
  50. Topert M, Olivar A, Opitz D. New developments in corticosteroid research. Journal of Dermatological Treatment 1 (Suppl. 5): 5–9, 1990CrossRefGoogle Scholar
  51. Vickers CFH. Existence of a reservoir in the stratum cor neum. Archives of Dermatology 88: 20–23, 1963PubMedCrossRefGoogle Scholar
  52. West DP, Worobec S, Solomon LM. Pharmacology and toxicology of infant skin. Journal of Investigative Dermatology 76: 147–150, 1981PubMedCrossRefGoogle Scholar
  53. Whitefiled M. Topical steroids. Lancet 29: 925, 1977CrossRefGoogle Scholar
  54. Yohn JJ, Weston WL. Topical glucocorticosteroids. In Weston WL, Mackle RM, Provost TT (Eds) Current problems in dermatology, vol. 2, Year Book Medical Publishers, Chicago, 1990Google Scholar
  55. Zaumseil RP, Furhmann H, Kecskes A, et al. Methylprednisolone aceponate (Advantan®) an effective topical corticoid therapy with few side effects. In von Macher A, Kolde G, Broker EB (Eds) Jahrbuch der Dermatologie, pp. 247–263, Biermann Verlag, Zülpich, 1992/1993Google Scholar
  56. Zaumseil RP, Kecskes A, Tauber U, et al. Methylprednisolone aceponate (MPA) —a new therapeutic for eczema: a pharmacological overview. Journal of Dermatological Treatment 3 (Suppl. 2): 3–7, 1992CrossRefGoogle Scholar

Copyright information

© Adis International Limited 1994

Authors and Affiliations

  • Moira Mori
    • 1
  • Nicola Pimpinelli
    • 1
  • Benvenuto Giannotti
    • 1
  1. 1.Dermatology Clinic IIUniversity of FlorenceFlorenceItaly

Personalised recommendations